vaccines

Population Immunity Shapes Evolution Of The Dengue Virus

The study from India shows why it would be beneficial to develop dengue vaccines locally to counter regional strains.

jeffrey seng, fish vaccines, fish diseases

Customizing Vaccines For Fish Health (VIDEO)

A shot or two could help keep fish diseases at bay and open floodgates to a more sustainable aquaculture practices in Asia, highlighted Dr. Jeffrey Seng.
2021 science stories, 2021 roundup

Asian Scientist Magazine’s 2021 Roundup

Here are 10 of Asian Scientist Magazine’s top stories in 2021, highlighting scientific advances in diverse domains from COVID-19 to climate change.

SARS-CoV-2 Variants, Explained

As new SARS-CoV-2 variants emerge, tried-and-tested solutions could be the key to stamping out COVID-19.

BioNTech Sets Its Sights On Singapore

BioNTech is headed for Southeast Asia, with Singapore set to host a fully operational regional office and mRNA production facility by 2023.

Asian Scientist Magazine’s April 2021 Roundup

Celebrate the region’s best scientists and their trailblazing efforts through Asian Scientist Magazine’s top stories from April 2021.

The Vaccine Vanguard

Vaccines are our best shot at finally overcoming the COVID-19 pandemic. Here’s a review on how vaccines work and where Asia’s leading vaccine candidates stand.
Founding executive director of Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore Medical School (Duke-NUS), Professor John Lim.

Rapid, Rigorous And Robust: How Singapore Approved Its COVID-19 Vaccines

No shortcuts were taken in the COVID-19 vaccine review processes, says Professor John Lim, executive director of the Centre of Regulatory Excellence at Duke-NUS Medical School.

Singapore To Be One Of The First Countries To Use Pfizer’s COVID-19 Vaccine

In addition to vaccines from Moderna, Pfizer-BioNTech and SinoVac, Singapore has placed orders for a homegrown vaccine developed by Duke-NUS Medical School.

Sinovac’s CoronaVac Trials Show Favorable Results

Early clinical trials show that Sinovac’s COVID-19 vaccine candidate safely induces an immune response in healthy volunteers within a month of vaccination.